InnoCare orelabrutinib data at ESMO 2026 shows durable responses
InnoCare Pharma presented three clinical datasets for its BTK inhibitor orelabrutinib at the European Society for Medical Oncology Congress 2026, covering two indications and treatment settings that span frontline therapy through to five-year follow-up in relapsed or refractory disease.
The Hong Kong and Shanghai-listed biopharmaceutical company said the data, delivered as posters and e-posters in Madrid, reinforce orelabrutinib's efficacy and tolerability profile across marginal zone lymphoma (MZL) and chronic lymphocytic leukaemia (CLL).
ZOOM trial: frontline MZL
The most mature dataset from the ZOOM trial, a multicentre single-arm Phase 2 study, examined orelabrutinib combined with zuberitamab, InnoCare's novel anti-CD20 monoclonal antibody, in previously untreated MZL patients. Among end-of-treatment evaluable patients, the best objective response rate (ORR) was 89.5% and the complete response rate was 73.7%. At a median follow-up of 9.1 months, median duration of response, progression-free survival (PFS) and overall survival had not been reached. The 12-month PFS rate was 95.2%, falling to 79.4% at 24 months, while the safety profile was described as manageable.
A second MZL dataset, drawn from a real-world retrospective study, examined sequential maintenance with orelabrutinib plus rituximab in intermediate- or high-risk patients. All evaluable patients entered maintenance having achieved at least a partial response after induction; following maintenance, 66.7% converted to complete response and the remainder maintained partial response, giving a post-maintenance ORR of 100%. Median PFS and overall survival were not reached. Notably, no atrial fibrillation or severe bleeding events were recorded, which is a clinically relevant observation for a BTK inhibitor class that has historically carried cardiovascular signal risk.
Five-year CLL follow-up
In relapsed or refractory CLL, InnoCare reported nearly five years of follow-up data from an earlier Phase 2 study. With a median follow-up of 57.8 months, the ORR stood at 93.8% and the complete response rate had deepened from 26.3% at interim analysis to 31.3% at data cutoff. Median PFS reached 50.8 months; median overall survival was not reached. No atrial fibrillation was observed across the follow-up period.
Competitive context and regulatory read-across
The BTK inhibitor class is well-established in B-cell malignancies, with ibrutinib, acalabrutinib and zanubrutinib holding significant market share in CLL and lymphoma. Orelabrutinib's competitive claim centres on selectivity: the drug is designed to reduce off-target kinase binding relative to first-generation BTK inhibitors, and the absence of atrial fibrillation across both datasets lends clinical weight to that positioning. Whether that translates into regulatory or commercial traction outside China, where orelabrutinib is already approved, will depend on InnoCare's filing strategy in the United States and Europe. The company has not announced an NDA or MAA submission timeline.
The ZOOM trial's combination with zuberitamab also represents a proprietary pairing that could differentiate InnoCare's commercial offering from combinations built on third-party CD20 agents such as rituximab or obinutuzumab. Investors will watch for randomised trial data and longer follow-up on PFS before MZL becomes a fully validated commercial indication in markets outside China.